Evidence map›Paper›PMID 27429843›Full record

ArticleAmerican journal of cancer research2016

Synthesis of a novel adamantyl nitroxide derivative with potent anti-hepatoma activity in vitro and in vivo.

Jin Sun, Shan Wang, Wei Bu, Meng-Ying Wei, Wei-Wei Li, Min-Na Yao, Zhong-Ying Ma, Cheng-Tao Lu, Hui-Hui Li, Na-Ping Hu and 4 more

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Nitroxides as Antioxidants and Anticancer Drugs.International journal of molecular sciences · 2017
    Review
  5. ROS-modulated therapeutic approaches in cancer treatment.Journal of cancer research and clinical oncology · 2017
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Jin SunDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical UniversityXi'an, Shaanxi 710032, China; College of Pharmacy, Shaanxi University of Chinese MedicineXianyang, Shaanxi 712046, China.
Shan WangDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University Xi'an, Shaanxi 710032, China.
Wei BuDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University Xi'an, Shaanxi 710032, China.
Meng-Ying WeiState Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, Fourth Military Medical University Xi'an, Shaanxi 710032, China.
Wei-Wei LiDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University Xi'an, Shaanxi 710032, China.
Min-Na YaoDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University Xi'an, Shaanxi 710032, China.
Zhong-Ying MaDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University Xi'an, Shaanxi 710032, China.
Cheng-Tao LuDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University Xi'an, Shaanxi 710032, China.
Hui-Hui LiCollege of Pharmacy, Shaanxi University of Chinese Medicine Xianyang, Shaanxi 712046, China.
Na-Ping HuCollege of Pharmacy, Shaanxi University of Chinese Medicine Xianyang, Shaanxi 712046, China.
En-Hu ZhangCollege of Pharmacy, Shaanxi University of Chinese Medicine Xianyang, Shaanxi 712046, China.
Guo-Dong YangState Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, Fourth Military Medical University Xi'an, Shaanxi 710032, China.
Ai-Dong WenDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University Xi'an, Shaanxi 710032, China.
Xiao-He ZhuDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University Xi'an, Shaanxi 710032, China.
Air Force Medical University · CNXijing Hospital · CNShaanxi University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, a novel adamantyl nitroxide derivative was synthesized and its antitumor activities in vitro and in vivo were investigated. The adamantyl nitroxide derivative 4 displayed a potent anticancer activity against all the tested human hepatoma cells, especially with IC50 of 68.1 μM in Bel-7404 cells, compared to the positive control 5-FU (IC50=607.7 μM). The significant inhibition of cell growth was also observed in xenograft mouse model, with low toxicity. Compound 4 suppressed the cell migration and invasion, induced the G2/M phase arrest. Further mechanistic studies revealed that compound 4 induced cell death, which was accompanied with damaging mitochondria, increasing the generation of intracellular reactive oxygen species, cleavages of caspase-9 and caspase-3, as well as activations of Bax and Bcl-2. These results confirmed that adamantyl nitroxide derivative exhibited selective antitumor activities via mitochondrial apoptosis pathway in Bel-7404 cells, and would be a potential anticancer agent for liver cancer.

Indexed as

Adamantyl nitroxide derivativeanticancerapoptosishepatomareactive oxygen species

Identifiers

PMID27429843
PMCPMC4937732
OpenAlexW2492711303

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.